A similar antibody-mediated targeting strategy was used with PLGA nanoparticles to deliver SLC3A2 siRNA into intestinal cells of mice with colitis [154], thereby targeting SLC3A2 on the surface of colon epithelial cells and macrophages, where it is overexpressed due to inflammatory processes [152,154]. Here, SLC3A2 is linked to colitis.